CRISPR Therapeutics AG
CRSP
$56.09
-$0.17-0.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -264.49% | 56.59% | 32.01% | -8.42% | -230.49% |
| Total Depreciation and Amortization | -2.19% | 2.17% | -2.19% | 0.25% | -1.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 230.76% | -53.63% | -5.45% | 40.57% | -19.29% |
| Change in Net Operating Assets | 325.21% | 39.65% | -484.71% | -95.02% | 203.19% |
| Cash from Operations | -7.83% | 53.20% | -11.85% | -187.09% | 214.24% |
| Capital Expenditure | 18.90% | -15.98% | 69.02% | 1.94% | 2.30% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -118.43% | 165.73% | -27.88% | -30.00% | -20.27% |
| Cash from Investing | -118.67% | 165.49% | -27.34% | -29.76% | -20.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -37.26% | 75.06% | -- | -- | 685.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -37.26% | 75.06% | 2,168.67% | -100.15% | 685.68% |
| Foreign Exchange rate Adjustments | 147.13% | -216.00% | 3,650.00% | 118.18% | -118.03% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -186.89% | 128.05% | -16.08% | -170.14% | 329.47% |